Literature DB >> 19464593

Applications of genomics in melanoma oncogene discovery.

Michael F Berger1, Levi A Garraway.   

Abstract

The identification of recurrent alterations in the melanoma genome has provided key insights into the biology of melanoma genesis and progression. These discoveries have come about as a result of the systematic deployment and integration of diverse genomic technologies, including DNA sequencing, chromosomal copy number analysis, and gene expression profiling. Here, the discoveries of several key melanoma oncogenes affecting critical cell pathways are described and the role played by evolving genomics technologies in melanoma oncogene discovery is examined. These advances are being exploited to improve prognosis and treatment of melanoma patients through the development of genome-based diagnostic and targeted therapeutic avenues.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464593      PMCID: PMC2687404          DOI: 10.1016/j.hoc.2009.03.005

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  107 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma.

Authors:  K Omholt; A Platz; U Ringborg; J Hansson
Journal:  Int J Cancer       Date:  2001-06-15       Impact factor: 7.396

3.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

4.  Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma.

Authors:  A Demunter; M Stas; H Degreef; C De Wolf-Peeters; J J van den Oord
Journal:  J Invest Dermatol       Date:  2001-12       Impact factor: 8.551

5.  Molecular classification of cutaneous malignant melanoma by gene expression profiling.

Authors:  M Bittner; P Meltzer; Y Chen; Y Jiang; E Seftor; M Hendrix; M Radmacher; R Simon; Z Yakhini; A Ben-Dor; N Sampas; E Dougherty; E Wang; F Marincola; C Gooden; J Lueders; A Glatfelter; P Pollock; J Carpten; E Gillanders; D Leja; K Dietrich; C Beaudry; M Berens; D Alberts; V Sondak
Journal:  Nature       Date:  2000-08-03       Impact factor: 49.962

6.  Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features.

Authors:  B C Bastian; P E LeBoit; D Pinkel
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

7.  Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601.

Authors:  B H Zhang; K L Guan
Journal:  EMBO J       Date:  2000-10-16       Impact factor: 11.598

8.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

Authors:  Hagop Kantarjian; Charles Sawyers; Andreas Hochhaus; Francois Guilhot; Charles Schiffer; Carlo Gambacorti-Passerini; Dietger Niederwieser; Debra Resta; Renaud Capdeville; Ulrike Zoellner; Moshe Talpaz; Brian Druker; John Goldman; Stephen G O'Brien; Nigel Russell; Thomas Fischer; Oliver Ottmann; Pascale Cony-Makhoul; Thierry Facon; Richard Stone; Carole Miller; Martin Tallman; Randy Brown; Michael Schuster; Thomas Loughran; Alois Gratwohl; Franco Mandelli; Giuseppe Saglio; Mario Lazzarino; Domenico Russo; Michele Baccarani; Enrica Morra
Journal:  N Engl J Med       Date:  2002-02-28       Impact factor: 91.245

9.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  8 in total

1.  Mutational status of naevus-associated melanomas.

Authors:  D Shitara; G Tell-Martí; C Badenas; M M S S Enokihara; L Alós; A B Larque; N Michalany; J A Puig-Butille; C Carrera; J Malvehy; S Puig; E Bagatin
Journal:  Br J Dermatol       Date:  2015-06-19       Impact factor: 9.302

Review 2.  The evolution of S100B inhibitors for the treatment of malignant melanoma.

Authors:  Kira G Hartman; Laura E McKnight; Melissa A Liriano; David J Weber
Journal:  Future Med Chem       Date:  2013-01       Impact factor: 3.808

3.  Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

Authors:  F Stephen Hodi; Christopher L Corless; Anita Giobbie-Hurder; Jonathan A Fletcher; Meijun Zhu; Adrian Marino-Enriquez; Philip Friedlander; Rene Gonzalez; Jeffrey S Weber; Thomas F Gajewski; Steven J O'Day; Kevin B Kim; Donald Lawrence; Keith T Flaherty; Jason J Luke; Frances A Collichio; Marc S Ernstoff; Michael C Heinrich; Carol Beadling; Katherine A Zukotynski; Jeffrey T Yap; Annick D Van den Abbeele; George D Demetri; David E Fisher
Journal:  J Clin Oncol       Date:  2013-06-17       Impact factor: 44.544

4.  Skin pigmentation polymorphisms associated with increased risk of melanoma in a case-control sample from southern Brazil.

Authors:  Larissa B Reis; Renato M Bakos; Fernanda S L Vianna; Gabriel S Macedo; Vanessa C Jacovas; André M Ribeiro-Dos-Santos; Sidney Santos; Lúcio Bakos; Patricia Ashton-Prolla
Journal:  BMC Cancer       Date:  2020-11-09       Impact factor: 4.430

5.  Integrative genomics identifies gene signature associated with melanoma ulceration.

Authors:  Zsuzsa Rakosy; Szilvia Ecsedi; Reka Toth; Laura Vizkeleti; Hector Hernandez-Vargas; Hector Herandez-Vargas; Viktoria Lazar; Gabriella Emri; Istvan Szatmari; Zdenko Herceg; Roza Adany; Margit Balazs
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

6.  DNA methylation characteristics of primary melanomas with distinct biological behaviour.

Authors:  Szilvia Ecsedi; Hector Hernandez-Vargas; Sheila C Lima; Laura Vizkeleti; Reka Toth; Viktoria Lazar; Viktoria Koroknai; Timea Kiss; Gabriella Emri; Zdenko Herceg; Roza Adany; Margit Balazs
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

7.  Reprogramming human A375 amelanotic melanoma cells by catalase overexpression: Reversion or promotion of malignancy by inducing melanogenesis or metastasis.

Authors:  Candelaria Bracalente; Noelia Salguero; Cintia Notcovich; Carolina B Müller; Leonardo L da Motta; Fabio Klamt; Irene L Ibañez; Hebe Durán
Journal:  Oncotarget       Date:  2016-07-05

8.  Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.

Authors:  Naoya Yamazaki; Arata Tsutsumida; Akira Takahashi; Kenjiro Namikawa; Shusuke Yoshikawa; Yutaka Fujiwara; Shunsuke Kondo; Akihira Mukaiyama; Fanghong Zhang; Yoshio Kiyohara
Journal:  J Dermatol       Date:  2018-02-05       Impact factor: 4.005

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.